Table 3. Treatment, dose, route, and duration of antivirals for H-MPVX.

PO: per oral; IV: intravenous; L: liter; CMV: cytomegalo virus; H-MPVX: human monkeypox infection

Source: Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance, 10 June 2022 [81]

Age group	Variables	Tecovirimat	Brincidofovir	Cidofovir
Adults	Route (Dose)	Oral: (600mg PO every 12 hours)   Intravenous:  (To be administered over 6 hours)   3 kg to < 35 kg: 6 mg/kg every 12 hours;   35 kg to < 120 kg: 200 mg every 12 hours;    > 120 kg: 300 mg every 12 hours	Oral:   < 10 kg: 6 mg/kg;   10–48 kg: 4 mg/kg;    > 48 kg: 200 mg (20 mL)	Intravenous:  5 mg/kg IV once weekly; Must be given with oral probenecid: 2 grams 3 hours prior to each dose and 1 gram at 2 and 8 hours after completion of the infusion;   Must be given with at least 1 L of 0.9% normal saline over a 1-2-hour period before each infusion
	Duration	14 days	Once weekly for 2 doses, on days 1 and 8	Once weekly × 2 weeks, then once every other week (Based on treatment for CMV retinitis)
Pediatrics	Route (Dose)	Oral:   13–25 kg: 200 mg every 12 hours;   25–40 kg: 400 mg every 12 hours;   > 40 kg: 600 mg every 12 hours   Intravenous: (Must be given over 6 hours)   3–35 kg: 6 mg/kg every 12 hours;   35–120 kg: 200 mg every 12 hours;    > 120 kg: 300 mg every 12 hours	Oral:   < 10 kg: 6 mg/kg;   10–48 kg: 4 mg/kg;   > 48 kg: 200 mg (20 mL)	Intravenous:    5 mg/kg IV once weekly;    Must be given with oral probenecid: 2 grams 3 hours prior to each dose and 1 gram at 2 and 8 hours after completion of the infusion;    Must be given with at least 1 L of 0.9% normal saline over a 1–2-hour period prior to each infusion.
	Duration	14 days	Once weekly for 2 doses, on days 1 and 8	Once weekly × 2 weeks, then once every other week (Based on treatment for CMV retinitis)